80,000 square feet FDA compliant manufacturing facility to produce an existing sales of $8MM and break even within one year not considering R&D expenses.
A rich product line of NDDS products.
Expected to launch 11 generic products With a market of $2 Billion in next 48 mths.
Technology transfer for most products already completed.
Specialty, Fully Integrated Pharmaceutical Company with an extensive pipeline of difficult to formulate, oral controlled release (OCR) branded and generic drugs, utilizing proprietary drug formulation and delivery technologies.
